Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377095 | 0.94 | DRD2 (0.57) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL30335968 | 0.90 | ALDH1A1 (0.57) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL516564 | 0.90 | ALDH1A1 (0.57) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL11674802 | 0.88 | DRD2 (0.66) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL10798638 | 0.86 | DRD2 (0.64) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL29381067 | 0.86 | DRD2 (0.62) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL715593 | 0.86 | ALDH1A1 (0.54) | TSHRF2 | |
| SCHEMBL27465 | 0.86 | DRD2 (0.62) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL12958255 | 0.84 | DRD2 (0.48) | DRD2DRD4DRD3L3MBTL1KDM4E | |
| SCHEMBL10000094 | 0.84 | MAPK1 (0.60) | DRD2DRD4DRD3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111465589-B | Compound having fluorene skeleton and method for producing same | 帝人株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-11339249-B2 | Compound having fluorene skeleton, and method for manufacturing same | TEIJIN LIMITED (JP) | 2022-05-24 | — | — | US | disclosed |
| EP-3747856-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | Teijin Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-20200354517-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | TEIJIN LIMITED (JP) | 2020-11-12 | — | — | US | disclosed |
| CN-111465589-A | Compound having fluorene skeleton and method for producing same | 帝人株式会社 | 2020-07-28 | — | — | CN | disclosed |
| WO-2020085222-A1 | CRYSTAL OF COMPOUND HAVING FLUORENE SKELETON AND METHOD FOR PRODUCING SAME | 帝人株式会社 | 2020-04-30 | — | — | WO | disclosed |
| WO-2019151264-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | 帝人株式会社 | 2019-08-08 | — | — | WO | disclosed |
| EP-2997029-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017037441-A1 | METHOD FOR PREPARING POLYOLS | ECONIC TECHNOLOGIES LIMITED (GB) | 2017-03-09 | — | — | WO | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20090012070-A1 | PESTICIDAL HETEROCYCLES | BAYER CROPSCIENCE AG (DE) | 2009-01-08 | — | — | US | disclosed |
| US-7417057-B2 | Pesticidal heterocycles | BAYER CROPSCIENCE AG (DE) | 2008-08-26 | — | — | US | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| EP-1499609-A4 | PESTICIDAL HETEROCYCLES | FMC CORP (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050143418-A1 | Pesticidal heterocycles | FMC CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1499609-A2 | PESTICIDAL HETEROCYCLES | FMC CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003092374-A2 | PESTICIDAL HETEROCYCLES | FMC CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
| US-4510088-A | FOR SYNTHETIC TEXTILES | CIBA GEIGY CORPORATION (US) | 1985-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012070-A1 | PESTICIDAL HETEROCYCLES | DDT, CBR3, ACHE | DRD2 618/4885DRD4 172/4885DRD3 239/4885 |
| US-20200354517-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | RFT1, AFF1, RER1 | DRD2 43/4885DRD4 118/4885DRD3 93/4885 |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | DRD2 113/4885DRD4 255/4885DRD3 142/4885 |
| US-11339249-B2 | Compound having fluorene skeleton, and method for manufacturing same | RFT1, AFF1, RER1 | DRD2 43/4885DRD4 118/4885DRD3 93/4885 |
| US-20050143418-A1 | Pesticidal heterocycles | DDT, TRHR, ACHE | DRD2 591/4885DRD4 173/4885DRD3 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.